$GENB
Generate Biomedicines, Inc. Common Stock
XNAS
Why is GENB down today? It is at $13.40 (-7.52%), and our scanner flagged it 16 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment GENB spikes, and full due diligence on GENB — key stats, earnings, dilution and insider activity. Free.
Get free $GENB alerts the moment volume spikes
Our scanner flagged $GENB 16 times in the last 30 days. Create a free account to track $GENB, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $13.40
- Change today
- -7.52%
- Previous close
- $14.49
- 52-week range
- $11.00 – $18.18
- Market cap
- $1.86B
- Institutional own.
- 71.92%
- Total held
- 100.0%
- Short interest
- 7.0M ▲ +18% vs prior · as of 2026-07-15
- Days to cover
- 9.4d
- Avg daily volume
- 720K
- Exchange
- XNAS
- 5m
- 0.1x
- 15m
- 0.2x
- 1h
- 1.5x
- 1D
- 0.2x
Get free GENB + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $GENB down today?
GENB is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 1 unusual-volume and momentum alert on GENB today, peaking at 2.5x its normal volume. Fresh from the SEC: Generate Biomedicines, Inc. filed a Quarterly report (10-Q). A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystGenerate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business UpdateReported Approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026Reported Revenue for the quarter ended June 30, 2026, was $6.3 million, compared with $10.1 million for the same period in 2025. This revenue reflects developments in the ongoing Amgen and Novartis research programs.Reported General and administrative expenses were $13.6 million for the quarter ended June 30, 2026, compared with $10.5 million for the same period in 2025. The increase was driven primarily by an increase in stock-based compensation., from the latest SEC filing. Read it →Insiders
6 open-market buys0 buys, 0 sells last 3 months (10/0 over 12 months)Show 10 recent transactionsMinimize 10 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Nally Michael Officer | Bought (open market) | +20K 0.02% of company | added 3.6% | 573K | $240K at $12.00 | Mar 4, 26 |
Afeyan Noubar Director | Acquired (grant/award) | +32.97M 25.7% of company | n/a | 13.70M | n/a | Mar 2, 26 |
Afeyan Noubar Director | Bought (open market) | +4.69M 3.7% of company | added 8.1% | 62.67M | $75.0M at $16.00 | Mar 2, 26 |
Mendillo Jane L Director | Bought (open market) | +2K | n/a | 2K | $24K at $16.00 | Mar 2, 26 |
Bancel Stephane Director | Acquired (grant/award) | +724K 0.6% of company | n/a | 724K | n/a | Mar 2, 26 |
Nally Michael Officer | Acquired (grant/award) | +658K 0.5% of company | added 40% | 2.32M | n/a | Mar 2, 26 |
Afeyan Noubar Director | Acquired (grant/award) | +32.97M 25.7% of company | n/a | 13.70M | n/a | Mar 2, 26 |
Afeyan Noubar Director | Bought (open market) | +4.69M 3.7% of company | added 8.1% | 62.67M | $75.0M at $16.00 | Mar 2, 26 |
Silvers Jason Officer | Bought (open market) | +2K | n/a | 2K | $32K at $16.00 | Mar 2, 26 |
Grous Beth Officer | Bought (open market) | +300 | n/a | 300 | $5K at $16.00 | Mar 2, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Recent offeringRecent priced share offering — a one-time sale that has already completed (not ongoing). If $GENB runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$GENB Sentiment
NeutralBlend of news sentiment, today’s move, and community votes. Not investment advice.
$GENB Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
GENB stock FAQ
Why is $GENB down today?
GENB is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 1 unusual-volume and momentum alert on GENB today, peaking at 2.5x its normal volume. Fresh from the SEC: Generate Biomedicines, Inc. filed a Quarterly report (10-Q). A material company disclosure like this is often the real catalyst behind a move of this size.
What is the GENB stock price today?
GENB last traded at $13.40, down 7.52% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live GENB alerts?
The GENB Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged GENB 16 times in the last 30 days.
What exchange is GENB on?
GENB (Generate Biomedicines, Inc. Common Stock) trades on XNAS, with a market cap of about $1.86B.
Is GENB good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge GENB for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.